SAN DIEGO, CA, Crystalys Therapeutics, a clinical-stage biopharmaceutical company, is announcing its launch with a $205 million Series A financing to support its mission of addressing the significant unmet medical needs of people living with gout.
The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors, including Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund. The financing round will support the advancement of global Phase 3 clinical studies evaluating the company's lead asset, dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential best-in-class safety and efficacy for the treatment of gout.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
